A Randomised, Double-Blind, Placebo Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/ or Metastatic Renal Cell Carcinoma

Trial Profile

A Randomised, Double-Blind, Placebo Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/ or Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Jul 2017 Results of retrospective analysis (n=343) assessing the prognostic significance of candidate cytokines and angiogenic factors for overall survival together with established clinical parameters and tumour burden, published in the British Journal of Cancer.
    • 11 Oct 2016 Results of cost effectiveness of COMPARZ and VEG105192 trials presented at the 41st European Society for Medical Oncology Congress.
    • 26 May 2016 Results (pooled analysis of this and other study, n = 1392) assessing Risk factors of proteinuria in mRCC patients treated with either pazopanib or sunitinib published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top